Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Small tyrosine kinase inhibitors (TKIs) from the anilinoquin...
| Class:Id | Summation:1169432 |
|---|---|
| _displayName | Small tyrosine kinase inhibitors (TKIs) from the anilinoquin... |
| _timestamp | 2011-04-04 14:39:54 |
| created | [InstanceEdit:1169430] Orlic-Milacic, Marija, 2011-01-18 |
| literatureReference | [LiteratureReference:1169414] Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity |
| modified | [InstanceEdit:1169436] Orlic-Milacic, Marija, 2011-01-18 [InstanceEdit:1181202] Orlic-Milacic, Marija, 2011-01-28 [InstanceEdit:1247620] Orlic-Milacic, Marija, 2011-04-04 |
| text | Small tyrosine kinase inhibitors (TKIs) from the anilinoquinazoline class selectively bind kinase domain of EGFR, competitively inhibiting ATP binding and subsequent autophosphorylation of EGFR dimers. EGFR kinase domain mutants sensitive to TKIs exhibit increased affinity for binding of TKIs than ATP compared with the wild-type EGFR protein, and are therefore preferential targets of small TKI therapeutics (Yun et al. 2007). |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Small tyrosine kinase inhibitors (TKIs) from the anilinoquin... (1169432)
